1. Generics Bulletin
  2. >>Products

Lilly Launches Lower-Priced Insulin Lispro

 
• By Dave Wallace

Eli Lilly has launched its authorized generic of its own Humalog (insulin lispro) brand in the US, at a 50% discount to the list price of the original.

PriceTag
Eli Lilly’s Humalog Authorized Generic Is Half The Price • Source: Shutterstock

Eli Lilly has launched an authorized generic version of its own Humalog (insulin lispro) 100U/ml in the US. Available in both vial and pen presentations, the generic has a list price of $137.35 for a single vial and $265.20 for a five-pack of KwikPens, representing a 50% discount to the diabetes brand’s list price.

“In addition to wholesaler contracts that have been secured, Lilly is working with payers to gain broad insurance coverage for

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.